Geovax receives notice of allowance for zika vaccine patent

Atlanta, ga, jan. 25, 2023 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the u.s. patent and trademark office issued a notice of allowance for patent application no. 17/000,768 titled, “method for generating a zikv immune response utilizing a recombinant modified vaccinia ankara vector encoding the ns1 protein.”
GOVX Ratings Summary
GOVX Quant Ranking